Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study

Documenti analoghi

• The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
  di: Xin Mu, et al.
  Pubblicazione: (2026)
• High Throughput Pharmacovigilance Screening for Roflumilast Adverse Effects in Real‐World Settings: A Sequence Symmetry Analysis
  di: Abdullah Abdelaziz, et al.
  Pubblicazione: (2025)
• Epigallocatechin‐3‐Gallate Provides Hepatoprotection Through Endoplasmic Reticulum Stress/TXNIP/NLRP3 Axis in Paracetamol‐Induced Acute Liver Injury
  di: Nagihan Demirtas, et al.
  Pubblicazione: (2025)
• Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis
  di: Jaehee Jung, et al.
  Pubblicazione: (2025)
• TCA Cycle Intermediate Mitigates Di(2‐ethylhexyl) Phthalate‐Induced Cholestatic Liver Injury Through Modulation of the Nrf2/NQO1 Signalling Axis
  di: Yue Jiang, et al.
  Pubblicazione: (2025)